Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Globus Medical (GMED – Research Report), Cochlear Limited (CHEOF – Research Report) and Nurix Therapeutics (NRIX – Research Report).
Globus Medical (GMED)
In a report issued on February 21, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Globus Medical, with a price target of $70.00. The company’s shares closed last Thursday at $55.26.
According to TipRanks.com, Chadha is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Globus Medical with a $66.56 average price target, a 21.0% upside from current levels. In a report issued on February 16, Stifel Nicolaus also maintained a Buy rating on the stock with a $61.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Cochlear Limited (CHEOF)
RBC Capital analyst Craig Wong-Pan upgraded Cochlear Limited to Hold on February 19 and set a price target of A$288.00. The company’s shares closed last Tuesday at $220.00, equals to its 52-week high of $220.00.
According to TipRanks.com, Wong-Pan is a 1-star analyst with an average return of
Cochlear Limited has an analyst consensus of Moderate Sell, with a price target consensus of $184.63, representing a -16.1% downside. In a report issued on February 12, Morgans also downgraded the stock to Hold with a A$290.50 price target.
Nurix Therapeutics (NRIX)
RBC Capital analyst Gregory Renza maintained a Buy rating on Nurix Therapeutics on February 20 and set a price target of $22.00. The company’s shares closed last Thursday at $10.55.
According to TipRanks.com, Renza is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Nurix Therapeutics with a $25.40 average price target, representing a 153.7% upside. In a report issued on February 5, Piper Sandler also maintained a Buy rating on the stock with a $35.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on GMED:
- Globus Medical price target raised to $64 from $61 at Stifel
- Globus Medical backs FY24 EPS view $2.68 to $2.70, consensus $2.69
- Globus Medical reports Q4 EPS 60c, consensus 61c
- Globus Medical Reports Fourth Quarter and Full Year 2023 Results
- Globus Medical Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call
